122 related articles for article (PubMed ID: 14534308)
1. Quantitative analysis of platelet alpha v beta 3 binding to osteopontin using laser tweezers.
Litvinov RI; Vilaire G; Shuman H; Bennett JS; Weisel JW
J Biol Chem; 2003 Dec; 278(51):51285-90. PubMed ID: 14534308
[TBL] [Abstract][Full Text] [Related]
2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Lisman T; Moschatsis S; Adelmeijer J; Nieuwenhuis HK; De Groot PG
Blood; 2003 Mar; 101(5):1864-70. PubMed ID: 12411291
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
6. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of platelet glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa.
Mazurov AV; Khaspekova SG; Byzova TV; Tikhomirov OYu ; Berndt MC; Steiner B; Kouns WC
FEBS Lett; 1996 Aug; 391(1-2):84-8. PubMed ID: 8706936
[TBL] [Abstract][Full Text] [Related]
8. The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin.
Helluin O; Chan C; Vilaire G; Mousa S; DeGrado WF; Bennett JS
J Biol Chem; 2000 Jun; 275(24):18337-43. PubMed ID: 10751402
[TBL] [Abstract][Full Text] [Related]
9. Concurrent signaling from Galphaq- and Galphai-coupled pathways is essential for agonist-induced alphavbeta3 activation on human platelets.
Paul BZ; Vilaire G; Kunapuli SP; Bennett JS
J Thromb Haemost; 2003 Apr; 1(4):814-20. PubMed ID: 12871420
[TBL] [Abstract][Full Text] [Related]
10. Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin.
Bennett JS; Chan C; Vilaire G; Mousa SA; DeGrado WF
J Biol Chem; 1997 Mar; 272(13):8137-40. PubMed ID: 9079626
[TBL] [Abstract][Full Text] [Related]
11. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
Lages B; Weiss HJ
Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
[TBL] [Abstract][Full Text] [Related]
12. Factor XIII mediates adhesion of platelets to endothelial cells through alpha(v)beta(3) and glycoprotein IIb/IIIa integrins.
Dardik R; Shenkman B; Tamarin I; Eskaraev R; Harsfalvi J; Varon D; Inbal A
Thromb Res; 2002 Feb; 105(4):317-23. PubMed ID: 12031826
[TBL] [Abstract][Full Text] [Related]
13. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Michelson AD; Furman MI; Goldschmidt-Clermont P; Mascelli MA; Hendrix C; Coleman L; Hamlington J; Barnard MR; Kickler T; Christie DJ; Kundu S; Bray PF
Circulation; 2000 Mar; 101(9):1013-8. PubMed ID: 10704169
[TBL] [Abstract][Full Text] [Related]
14. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
15. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Lele M; Sajid M; Wajih N; Stouffer GA
Circulation; 2001 Jul; 104(5):582-7. PubMed ID: 11479257
[TBL] [Abstract][Full Text] [Related]
16. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
17. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
18. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
19. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
Kuo YR; Jeng SF; Wang FS; Huang HC; Wei FC; Yang KD
J Surg Res; 2002 Sep; 107(1):50-5. PubMed ID: 12384064
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
